Solid Biosciences Rises as Investors Focus on Rare-Disease Pipeline
Solid Biosciences shares closed at $7.24 Thursday, up 6% ahead of the Nasdaq open. H.C. Wainwright raised its price target to $25, citing progress in Solid’s Friedreich’s ataxia program. Two patients have received SGT-212 in a Phase 1b trial with no serious adverse events reported. Solid will present at the Goldman Sachs healthcare conference on June 8.